Bivalent linkers and conjugates thereof

ABSTRACT

Bivalent linkers derived from compounds of formulae (V), (VI), and (VII), where X 1  and X 2  are leaving groups and the other variables are as defined in the claims, to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.

CROSS REFERENCE TO RELATED APPLICATION

This application claims the priority benefit under 35 U.S.C. § 119(e) ofU.S. provisional patent application Ser. No. 60/590,580, filed Jul. 23,2004, the disclosure of which is incorporated herein in its entirety byreference.

FIELD OF THE INVENTION

This invention pertains to bivalent linkers, and the synthesis and usethereof. In particular, this invention pertains to the synthesis and useof bivalent linkers in preparing vitamin, drug, diagnostic agent, and/orimaging agent conjugates.

BACKGROUND

Drug, vitamin, diagnostic, and imaging agent conjugates have been usedto treat, diagnose, and evaluate various disease states in humans and inanimals. In many cases these drug, vitamin, diagnostic, and imagingagent conjugates include intervening linkers separating for example atargeting ligand from a drug, diagnostic agent, or imaging agent. Theselinkers include a wide variety of bivalent fragments that may be usedseparately or when linked together for inclusion in conjugates to forexample space a drug, diagnostic agent, or imaging apart from otherparts of the conjugate, such as for example a vitamin or other targetingligand. These linkers may also be stable to the metabolic,physiological, or biological conditions present when they areadministered to humans and animals, or alternatively these linkers mayundergo various routes of cleavage and/or fragmentation under suchconditions. There exists a continuing need for bivalent linkers that canbe generally used in drug, vitamin, diagnostic, and imaging agentconjugates.

SUMMARY OF THE INVENTION

Illustratively, the present invention includes divalent linkers, whichare alternatively referred to as bivalent linkers, that may be used tocouple, link, bond, attach, or otherwise associate two or more chemicalentities. This coupling, linking, attachment, or association may be usedin the formation of conjugates of such chemical entities. Those chemicalentities include targeting ligands and receptor-binding ligands, such asvitamins. Those chemical entities also include drugs for treatingvarious diseases or disease states, and imaging and diagnostic agentsfor diagnosing, detecting, or otherwise monitoring various diseases ordisease states.

In one embodiment, one chemical entity includes a vitaminreceptor-binding moiety, and another entity includes a drug, imagingagent, diagnostic agent, another bivalent linker, or another bivalentlinker conjugated with a drug, imaging agent, diagnostic agent. It isappreciated that multiple linkers may be used between the two or morechemical entities to change the distance between the two entities and/orto change the physicochemical properties of the conjugates preparedtherefrom.

In another embodiment, a compound is described that includes a firstleaving group that is displaceable by a first nucleophile, a linkerregion, and a second leaving group that is displaceable by a secondnucleophile, wherein the first nucleophile is a vitamin receptor-bindingmoiety, and the linker region comprises one or more bivalent linkerunits, which may be the same or different, and the second nucleophile isa drug, imaging agent, diagnostic agent, or another bivalent linker.

In another embodiment, a compound having the structure (V) is described

wherein n is an integer from 1 to about 4; R^(a) and R^(b) are eachindependently selected from the group consisting of hydrogen and alkyl,including lower alkyl such as C₁-C₄ alkyl that are optionally branched;or R^(a) and R^(b) are taken together with the attached carbon atom toform a carbocyclic ring; and X¹ and X² are each independently selectedleaving groups. In one aspect, each of the independently selectedleaving groups X¹ and X² are displaceable by a nucleophile, such as adrug, a vitamin, an imaging agent, a diagnostic agent, or anotherbivalent linker nucleophile, and the like.

In another embodiment, a conjugate is formed from the compound offormula (V) by displacing one or more of the leaving groups X¹ and X²with a nucleophile, such as a drug, a vitamin, an imaging agent, adiagnostic agent, or another bivalent linker nucleophile, and the like.

In another embodiment, a compound having the structure (VI) is described

wherein m is an integer from 1 to about 4; and X¹ and X² are eachindependently selected leaving groups. In one aspect, each of theindependently selected leaving groups X¹ and X² is displaceable by anucleophile, such as a drug, a vitamin, an imaging agent, a diagnosticagent, or another bivalent linker nucleophile, and the like.

In another embodiment, a conjugate is formed from the compound offormula (VI) by displacing one or more of the leaving groups X¹ and X²with a nucleophile, such as a drug, a vitamin, an imaging agent, adiagnostic agent, or another bivalent linker nucleophile, and the like.

In another embodiment, a compound having the structure (VII) isdescribed

wherein m is an integer from 1 to about 4; and X¹ and X² are eachindependently selected leaving groups. In one aspect, each of theindependently selected leaving groups X¹ and X² is displaceable by anucleophile, such as a drug, a vitamin, an imaging agent, a diagnosticagent, or another bivalent linker nucleophile, and the like.

In another embodiment, a conjugate is formed from the compound offormula (VII) by displacing one or more of the leaving groups X¹ and X²with a nucleophile, such as a drug, a vitamin, an imaging agent, adiagnostic agent, or another bivalent linker nucleophile, and the like.

In one aspect, the conjugate has one of the following structures (VIII)

wherein n is an integer from 1 to about 4; R^(a) and R^(b) are eachindependently selected from the group consisting of hydrogen and alkyl,including lower alkyl such as C₁-C₄ alkyl that are optionally branched;or R^(a) and R^(b) are taken together with the attached carbon atom toform a carbocyclic ring; X¹ and X² are each independently selectedleaving groups; and L¹ and L² are each independently selected bivalentlinkers.

In another embodiment, the conjugate has one of the following structures(IX)

wherein m is an integer from 1 to about 4; X¹ and X² are eachindependently selected leaving groups; and L¹ and L² are eachindependently selected bivalent linkers.

In another embodiment, the conjugate has one of the following structures(X)

wherein m is an integer from 1 to about 4; X¹ and X² are eachindependently selected leaving groups; and L¹ and L² are eachindependently selected bivalent linkers.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 a shows the mass spectrum of Example 1, compound 5;

FIG. 1 b shows the ¹H NMR spectrum of Example 1, compound 5;

FIG. 2 shows the ¹H NMR spectrum of Example 3, compound 10; and

FIG. 3 shows the ¹H NMR spectrum of Example 4, compound 12.

DETAILED DESCRIPTION

Bivalent linkers for use in conjugates or for use in preparingconjugates are described herein. The bivalent linkers may be used toprepare drug conjugates, imaging agent conjugates, and/or diagnosticagent conjugates. Drug conjugates include targeting agent conjugates,such as the vitamin receptor-binding drug conjugates as described inU.S. Patent Application Publication No. US-2005-0002942-A1, and otherdrug conjugates described in U.S. Patent Application Publications Nos.US-2001-0031252-A1 and US-2003-0086900-A1. Imaging agent conjugates anddiagnostic agent conjugates include those described in U.S. PatentApplication Publication No. US-2004-0033195-A1 and International PatentApplication Publication No. WO 03/097647. The disclosures of each of theforegoing patent application publications are incorporated herein byreference.

It is appreciated that conjugates of analogs and derivatives of drugs,conjugates of analogs and derivatives of vitamins, conjugates of analogsand derivatives of imaging agents, and conjugates of analogs andderivatives of diagnostic agents may be prepared using the bivalentlinkers described herein. Further, unless otherwise indicated, the termdrug should be understood to include analogs and derivatives thereof,the term vitamin should be understood to include analogs and derivativesthereof, the term imaging agent should be understood to include analogsand derivatives thereof, and the term diagnostic agent should beunderstood to include analogs and derivatives thereof.

The bivalent linkers described herein may be used as spacers to alterthe overall distance from the drug, vitamin, imaging agent, ordiagnostic agent and the moiety to which it is conjugated. Further, thebivalent linkers described herein may be used to alter thephysicochemical properties, solubility properties, and other propertiesof the drug, vitamin, imaging agent, or diagnostic agent conjugates inwhich they are included.

Illustratively, the bivalent linkers described herein may by included inlinkers used to prepare vitamin receptor-binding drug conjugates,vitamin receptor-binding imaging agent conjugates, and vitaminreceptor-binding diagnostic agent conjugates of the formulae (I)

where V is a vitamin receptor-binding moiety, including analogs orderivatives thereof, L is a linker, D is a drug, including analogs orderivatives thereof, IA is an imaging agent, including analogs orderivatives thereof, and DA is a diagnostic agent, including analogs orderivatives thereof. Linker (L) can comprise multiple bivalent linkers,including the bivalent linkers described herein.

In one embodiment, the bivalent linkers described herein are compoundsof formulae (II)

where n is an integer selected from 1 to about 4; R^(a) and R^(b) areeach independently selected from the group consisting of hydrogen andalkyl, including lower alkyl such as C₁-C₄ alkyl that are optionallybranched; or R^(a) and R^(b) are taken together with the attached carbonatom to form a carbocyclic ring; R is an optionally substituted alkylgroup, an optionally substituted acyl group, or a suitably selectednitrogen protecting group; and (*) indicates points of attachment forthe drug, vitamin, imaging agent, diagnostic agent, other bivalentlinkers, or other parts of the conjugate.

In another embodiment, the bivalent linkers described herein includecompounds of formulae (III)

where m is an integer selected from 1 to about 4; R is an optionallysubstituted alkyl group, an optionally substituted acyl group, or asuitably selected nitrogen protecting group; and (*) indicates points ofattachment for the drug, vitamin, imaging agent, diagnostic agent, otherbivalent linkers, or other parts of the conjugate.

In another embodiment, the bivalent linkers described herein includecompounds of formulae (IV)

where m is an integer selected from 1 to about 4; R is an optionallysubstituted alkyl group, an optionally substituted acyl group, or asuitably selected nitrogen protecting group; and (*) indicates points ofattachment for the drug, vitamin, imaging agent, diagnostic agent, otherbivalent linkers, or other parts of the conjugate.

In another embodiment, the bivalent linkers described herein includecompounds of formulae (V), (VI), and (VII)

wherein n and m are each independently selected integers from 1 to about4; R^(a) and R^(b) are each independently selected from the groupconsisting of hydrogen and alkyl, including lower alkyl such as C₁-C₄alkyl that are optionally branched; or R^(a) and R^(b) are takentogether with the attached carbon atom to form a carbocyclic ring; andX¹ and X² are each independently selected leaving groups that may benucleophilically displaced by a drug, vitamin, imaging agent, diagnosticagent, another bivalent linker, or another part of the conjugate.

Illustratively, vitamin-drug conjugates that may be formed from thebivalent linkers described herein include compounds of formulae (VIII)

where V, D, and n are as described herein; n is an integer from 1 toabout 4; R^(a) and R^(b) are each independently selected from the groupconsisting of hydrogen and alkyl, including lower alkyl such as C₁-C₄alkyl that are optionally branched; or R^(a) and R^(b) are takentogether with the attached carbon atom to form a carbocyclic ring; andL¹ and L² are each independently selected bivalent linkers used toprepare the conjugates. Similarly, it is understood that thevitamin-imaging agent and vitamin-diagnostic agent conjugatescorresponding to the formulae (VIII) may also be formed from thebivalent linkers described herein.

Illustratively, vitamin-drug conjugates that may be formed from thebivalent linkers described herein include compounds of formulae (IX)

where V, D, and n are as described herein; m is an integer from 1 toabout 4; and L¹ and L² are each independently selected bivalent linkersused to complete the conjugates. Similarly, it is understood that thevitamin-imaging agent and vitamin-diagnostic agent conjugatescorresponding to the formulae (IX) may also be formed from the bivalentlinkers described herein.

Illustratively, vitamin-drug conjugates that may be formed from thebivalent linkers described herein include compounds of formulae (X)

where V, D, and n are as described herein; m is an integer from 1 toabout 4; and L¹ and L² are each independently selected bivalent linkersused to complete the conjugates. Similarly, it is understood that thevitamin-imaging agent and vitamin-diagnostic agent conjugatescorresponding to the formulae (X) may also be formed from the bivalentlinkers described herein.

It is to be further understood that when any of V, L², and/or D isconnected to the carbonyl group of the bivalent linkers describedherein, such as the bivalent linkers of formulae (VIII), (IX), and/or(X), the connection is made through a heteroatom, such as an oxygen,sulfur, optionally substituted nitrogen, and the like.

In another illustrative embodiment, intermediates useful for preparingdrug, vitamin, imaging agent, or diagnostic agent conjugates aredescribed herein. Such intermediates may be subsequently linked to othercomponents to form vitamin, imaging agent, or diagnostic agentconjugates. Intermediates described herein include compounds of formulaeXI

where V, D, L¹, L², X¹, and X² are as described herein; and n is aninteger from 1 to about 4. Similarly, it is understood that thevitamin-imaging agent and vitamin-diagnostic agent conjugatescorresponding to the formulae (XI) may also be formed from the bivalentlinkers described herein.

Illustratively, vitamin-drug conjugates that may be formed from thebivalent linkers described herein include compounds of formulae (XII)

where V, D, L¹, L², X¹, and X² are as described herein; and m is aninteger from 1 to about 4. Similarly, it is understood that thevitamin-imaging agent and vitamin-diagnostic agent conjugatescorresponding to the formulae (XII) may also be formed from the bivalentlinkers described herein.

Illustratively, vitamin-drug conjugates that may be formed from thebivalent linkers described herein include compounds of formulae (XIII)

where V, D, L¹, L², X¹, and X² are as described herein; and m is aninteger from 1 to about 4. Similarly, it is understood that thevitamin-imaging agent and vitamin-diagnostic agent conjugatescorresponding to the formulae (XIII) may also be formed from thebivalent linkers described herein.

It is further understood that when any of V, L², and/or D is connectedto the carbonyl group of the bivalent linkers described herein, such asthe bivalent linkers of formulae (XI), (XII), and (XIII), the connectionis made through a heteroatom, such as an oxygen, sulfur, optionallysubstituted nitrogen, and the like.

In one illustrative embodiment, the leaving group X¹ is an arylthiogroup. In one aspect, the arylthio group is an heteroarylthio group andincludes, but is not limited to, optionally substituted 2-pyridinylthio,optionally substituted 4-pyridinylthio, and the like. In anotherillustrative aspect, the substitutions include electron withdrawingsubstituents, such as cyano, nitro, alkylsulfonyl, arylsulfonyl, halo,haloalkyl, acyl and derivatives thereof, carboxyl and derivativesthereof, and the like, and combinations thereof.

In another illustrative embodiment, the leaving group X² is an aryloxygroup. In one aspect, the aryloxy group is an optionally substitutedphenyl group. In another illustrative aspect, the aryloxy group is anoptionally substituted heteroaryloxy group and includes, but is notlimited to, optionally substituted benzotriazoles, and the like. Inanother illustrative aspect, the substitutions include electronwithdrawing substituents, such as cyano, nitro, alkylsulfonyl,arylsulfonyl, halo, haloalkyl, acyl and derivatives thereof, carboxyland derivatives thereof, and the like, and combinations thereof.

Illustrative leaving groups X¹ include compounds of formulae (XIV)

where (*) indicates the point of attachment to the sulfur of thebivalent linkers described herein. In one aspect, each of the leavinggroups X¹ having the formulae (XIV) may be optionally substituted withone or more substituents, or additional substituents, selected fromhalo, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, and the like.Further illustrative leaving groups include alkyl and arylsulfonylleaving groups, such as but not limited to

where R is alkyl or aryl, each of which may be optionally substituted,such as with halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro,and the like; and where (*) indicates the point of attachment to thesulfur of the bivalent linkers described herein.

Illustrative leaving groups X² include compounds of formulae (XV)

where (*) indicates the point of attachment to the carbonyl of thebivalent linkers described herein. In one aspect, each of the leavinggroups X² having the formulae (XV) may be optionally substituted withone or more substituents, or additional substituents, selected fromhalo, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, and the like.

Bivalent linkers that include leaving groups such as those shown informulae XIII, XIV, and XV may be prepared following the correspondingsynthetic procedures described in the Examples described herein.

In another illustrative aspect, the vitamin receptor binding drugdelivery conjugate intermediate described herein includes a compoundhaving the formulae:

or a protected derivative thereof, where R^(a) and R^(b) are eachindependently selected from the group consisting of hydrogen and alkyl,including lower alkyl such as C₁-C₄ alkyl that are optionally branched;or R^(a) and R^(b) are taken together with the attached carbon atom toform a carbocyclic ring; Y is hydrogen or a substituent, illustrativelyan electron withdrawing substituent, including but not limited to nitro,cyano, halo, alkylsulfonyl, a carboxylic acid derivative, and the like;l_(s) is either a bond or another bivalent linker; and where V is asdefined herein. It is appreciated that other substituents may beoptionally present on the cysteine or homocysteine portion of these drugdelivery conjugates, such as longer and/or branched alkyl groups, alkoxygroups, alkoxyalkyl groups, and the like. It is to be understood thatcyclic variants of the cysteine portion of these drug deliveryconjugates are contemplated. In one aspect, R^(a) is hydrogen, and R^(b)is alkyl, such as methyl. In another aspect, both R^(a) and R^(b) arealkyl, either the same or different, such as both being methyl. Inanother aspect, R^(a) and R^(b) are taken together with attached carbonto form a spiro cyclopropyl.

In another illustrative aspect of the vitamin receptor binding drugdelivery conjugate intermediate described herein, the intermediateincludes compounds having the formulae:

or protected derivatives thereof, where V is the vitamin, or an analogor a derivative thereof, AA is an amino acid, illustratively selectedfrom the naturally occurring amino acids, or stereoisomers thereof,R^(a) and R^(b) are each independently selected from the groupconsisting of hydrogen and alkyl, including lower alkyl such as C₁-C₄alkyl that are optionally branched, or R^(a) and R^(b) are takentogether with the attached carbon atom to form a carbocyclic ring, Y ishydrogen or a substituent, illustratively an electron withdrawingsubstituent, including but not limited to nitro, cyano, halo,alkylsulfonyl, a carboxylic acid derivative, and the like, n and m areindependently selected integers, such as 1, 2, or 3, and p is an integersuch as 1, 2, 3, 4, or 5. It is appreciated that other substituents maybe optionally present on the cysteine or homocysteine portion of thesedrug delivery conjugates, such as longer and/or branched alkyl groups,alkoxy groups, alkoxyalkyl groups, and the like. It is to be understoodthat cyclic variants of the cysteine portion of these drug deliveryconjugates are contemplated. AA can also be any other amino acid, suchas any amino acid having the general formula:

—N(R)—(CR′R″)_(q)—C(O)—

where R is hydrogen, alkyl, acyl, or a suitable nitrogen protectinggroup, R′ and R″ are hydrogen or a substituent, each of which isindependently selected in each occurrence, and q is an integer such as1, 2, 3, 4, or 5. Illustratively, R′ and/or R″ independently correspondto, but are not limited to, hydrogen or the side chains present onnaturally occurring amino acids, such as methyl, benzyl, hydroxymethyl,thiomethyl, carboxyl, carboxylmethyl, guanidinopropyl, and the like, andderivatives and protected derivatives thereof. The above describedformula includes all stereoisomeric variations. For example, the aminoacid may be selected from asparagine, aspartic acid, cysteine, glutamicacid, lysine, glutamine, arginine, serine, ornitine, threonine, and thelike. In another illustrative aspect of the vitamin receptor bindingdrug delivery conjugate intermediate described herein, the drug, or ananalog or a derivative thereof, includes an alkylthiol nucleophile.

It is appreciated that the bivalent linkers described herein may undergocleavage under certain chemical, environmental, or physiologicalconditions. In particular, the bivalent linkers described herein mayundergo cleavage under physiological conditions, such as by the actionof a glutathione mediated mechanism. In such embodiments, those linkersmay be alternatively referred to as releasable linkers.

Illustrative mechanisms for cleavage of the bivalant linkers describedherein include the following 1,4 and 1,6 fragmentation mechanisms

where X is an exogenous or endogenous nucleophile, glutathione, orbioreducing agent, and the like, and either of Z or Z′ is the vitamin,or analog or derivative thereof, or the drug, or analog or derivativethereof, or a vitamin or drug moiety in conjunction with other portionsof the bivalent linker. It is to be understood that although the abovefragmentation mechanisms are depicted as concerted mechanisms, anynumber of discrete steps may take place to effect the ultimatefragmentation of the bivalent linker to the final products shown. Forexample, it is appreciated that the bond cleavage may also occur by acidcatalyzed elimination of the carbamate moiety, which may beanchimerically assisted by the stabilization provided by either the arylgroup of the beta sulfur or disulfide illustrated in the above examples.In those variations of this embodiment, the releasable linker is thecarbamate moiety. Alternatively, the fragmentation may be initiated by anucleophilic attack on the disulfide group, causing cleavage to form athiolate. The thiolate may intermolecularly displace a carbonic acid orcarbamic acid moiety and form the corresponding thiacyclopropane. In thecase of the benzyl-containing bivalent linkers, following anillustrative breaking of the disulfide bond, the resulting phenylthiolate may further fragment to release a carbonic acid or carbamicacid moiety by forming a resonance stabilized intermediate. In any ofthese cases, the releaseable nature of the illustrative bivalent linkersdescribed herein may be realized by whatever mechanism may be relevantto the chemical, metabolic, physiological, or biological conditionspresent.

General Disulfide Formation

Disulfide groups can be generally formed by reacting an alkyl or arylsulfonylthioalkyl derivative, or the corresponding heteroaryldithioalkylderivative such as a pyridin-2-yldithioalkyl derivative, and the like,with an alkylenethiol derivative, as illustrated in Scheme 1.

Solvents that can be used for this reaction include THF, EtOAc, CH₂Cl₂,CHCl₃, CCl₄, DMF, DMSO, and the like. The temperature range employed inthis transformation may vary between 0° C. and 80° C. The required alkylor aryl sulfonylthioalkyl derivative may be prepared usingart-recognized protocols, and also according to the method of Ranasingheand Fuchs, Synth. Commun. 18(3), 227-32 (1988), the disclosure of whichis incorporated herein by reference. Other methods of preparingunsymmetrical dialkyl disulfides are based on a transthiolation ofunsymmetrical heteroaryl-alkyl disulfides, such as 2-thiopyridinyl,3-nitro-2-thiopyridinyl, and like disulfides, with alkyl thiol, asdescribed in WO 88/01622, European Patent Application No. 0116208A1, andU.S. Pat. No. 4,691,024, the disclosures of which are incorporatedherein by reference.

General Carbonate Thiocarbonate and Carbamate Formation

Carbonates, thiocarbonates, and carbamates can generally be formed byreacting an hydroxy-substituted compound, a thio-substituted compound,or an amine-substituted compound, respectively, with an activatedalkoxycarbonyl derivative where X is a suitable leaving group, asillustrated in Scheme 2.

where Q is oxygen, sulfur, optionally substituted nitrogen, optionallyprotected nitrogen, and the like. Solvents that can be used for thisreaction include THF, EtOAc, CH₂Cl₂, CHCl₃, CCl₄, DMF, DMSO, and thelike. The temperature range employed in this transformation may varybetween 0° C. and 80° C. Any basic catalyst such as an inorganic base,an amine base, a polymer bound base, and the like can be used tofacilitate the reaction.

EXAMPLES Example 16-Trifluoromethyl-1-[2-(2-pyridinyldithio)ethoxycarbonyloxy]benzotriazole

Example 1 was prepared according to Scheme 3.

(a) 4-dimethylaminopyridine (DMAP), CH₂Cl₂; (b) Et₂O; (c) CH₃CH.

Step (a). A solution of 4-(dimethylamine)pyridine (3.0 g; 24.68 mmol;1.03 eqs.) in 10 mL anhydrous methanol was added to a suspension of2-(2-pyridyldithio)ethanol hydrochloride (compound (1a); C₇H₉NS₂O.HCl;5.4 g; 24 mmol) in 10 ml of anhydrous methanol, and the mixture wasstirred to form a clear solution. Within a few minutes, the solutionturned turbid with the formation of a fine suspension, and thissuspension was purified by flash chromatography (FC). FC was performedby using 140 g silica gel 60 with 5% methanol in CH₂Cl₂ to form a 24cm×4.3 cm silica gel bed with 500 ml solvent reservoir. The saidsuspension in 20 mL CH₂Cl₂ was loaded and the column was eluted with 5%methanol in CH₂Cl₂ with standard collection of 30 mL fractions coupledwith UV-detection. The product compound (1b) can be detected fromfraction 2 to 9 by TLC (1:1 Hexane:EtOAc).

Step (b). 1-Hydroxy-6-(trifluoromethyl)benzotriazole (compound (2);C₇H₄F₃N₃O; 2.3 g; 0.11 mol; Aldrich) was dissolved in 770 mL ether andthe supernatant was decanted into a 2 L RB flask Trichloromethylchloroformate (compound (3); C₂Cl₄O₂; 107 g; 0.053 mol; 6.0 mL) wasadded into this clean colorless solution at room temperature over a 15minutes period. The mixture was gently heated to temperature between40-50° C. for 1 hour, and cooled to room temperature. The solution wasfiltered, and the precipitate was washed with ether (10×30 mL). Theprecipitate was a white powder and was dried with vacuum and gave 16.95g (74% yield). Additional synthetic details are described by Ogura etal, in Synthesis, 1987, 557-560, the disclosure of which is incorporatedherein by reference.

Step (c). A solution of compound (1b) (ca. 7.5 mmol) in 10 mLacetonitrile was added over a 2 minutes period to a stirred cleansolution of compound 4 (3.46 g; 8 mmol) in 300 ml acetonitrile at roomtemperature. The mixture was then stirred at room temperature for 24hours. TLC analysis of the mixture was performed after 24 hours. Themixture was allowed to be stirred for additional 14 hours to a total of38 hours. The mixture was concentrated and washed with 50 mL of 1NNaHCO₃ eq. and 100 mL of ethyl acetate. The organic layer was separated,washed further with 1 N NaHCO₃ eq. (1×10 mL), dried (Na₂SO₄), andfiltered, to give a white solid powder, which was dried on vacuum for 5hours and gave 2.54 g.

Example 2

Example 2 was prepared according to Scheme 4.

2-(2-pyridyldithio)ethanol hydrochloride (compound (1b); 8.8 g; 39.33mL) was dissolved in 78 mL CH₂Cl₂, and 2 eqs. of pyridine (C₅H₅N; 80.88mL) was added. para-Nitrophenyl chloroformate (compound (6); 8.08 g; 40mmol) was dissolved in 80 mL CH₂Cl₂, and the solution was added tomixture of 2-(2-pyridyldithio)ethanol hydrochloride and pyridine over a15 minutes period. The resultant clear solution was stirred at roomtemperature for 15 hours. TLC analysis for the above mixture after 15hours stirring indicated completion of the reaction. The mixture wasthen filtered to remove precipitated pyridine hydrochloride. The lightyellow clear filtrate was washed with deionized water (2×50 mL) toremove the dissolved pyridine hydrochloride, dried (Na₂SO₄), filtered,and concentrated with vacuum (13.8 g). Silica gel 60 (250 g) in CH₂Cl₂was used to from a 50 cm×4.2 cm of silica gel bed with 250 mL solventreservoir. The product compound (7), ca. 13.8 g, was dissolved in 15 mL(10 mL+5 mL) of CH₂Cl₂ and the solution was loaded with an elution ratioof 30 mL/min with standard collection of 30 mL fractions coupled withUV-detection and gave 13.3 g (96% yield).

Example 3

Example 3 was prepared according to Scheme 5.

3-Nitro-2-pyridinesulfenyl chloride (compound (8)) was dissolved in 15mL anhydrous CH₂Cl₂. The solution was cooled by an ice bath. 4-ethanoylthiophenol (compound (9)) was dissolved in 10 mL CH₂Cl₂ and added to adropping funnel affixed to the container containing3-nitro-2-pyridinesulfenyl chloride solution. The solution of 4-ethanoylthiophenol was added over a 2 to 5 minute period. After the solution of4-ethanoyl thiophenol was added, the mixture was allowed to warm to roomtemperature and then stirred for 2 hours. While addition of 4-ethanoylthiophenol, a precipitate formed. After the 2 hours period of stirringat room temperature was completed, the mixture was sonicated for 5minutes and the precipitate dissolved. TLC analysis showed a new spotformed in addition to 3-nitro-2-pyridinesulfenyl chloride and 4-ethanoylthiophenol. The reaction mixture was washed with saturated NaHCO₃. Theorganic layer was supplemented with an addition 100 mL Ch₂Cl₂. Theproduct was dried for 3 hours under vacuum.

Example 4

Example 4 was prepared according to Scheme 6.

Compound (10) (0.025 g; 0.085 mmol) was dissolved in anhydrous CH₂Cl₂under stirring. para-Nitrophenyl cholorofomate (compound (11); 0.020 g;1.2 eq.) was added along with 1 eq. of triethylamine (TEA) to thestirring solution. TLC analysis showed that compound (10) was consumedafter 2 hours. The product compound (12) was isolated by columnchromatography (7:3 Hexane:EtOAc).

Example 5 General Preparation of Compounds Containing a CysteineDisulfide Bond

Any of thiosulfonates (13) (1 eq.), prepared according to the method ofRanasinghe and Fuchs, Synth. Commun. 18(3), 227-32 (1988), thedisclosure of which is incorporated herein by reference, are reactedwith drugs, drug analogs, or drug derivatives (14) (1 eq.) to preparethe drug thiosulfonates (15) as a solution in methanol, as shown inScheme 7.

Referring to Scheme 7, R is alkyl or aryl, L is a suitable leavinggroup, such as halogen, pentafluorophenyl, and the like, n is an integerfrom 1 to about 4, and X is —O—, —NH—, —C(O)O—, or —C(O)NH—. Conversionis conveniently monitored by observing the disappearance of eachstarting material by TLC (silica gel; CHCl₃/MeOH=9/1). Final yield was83% (mass of removed product was 32 mg from a total yield of 38.9 mg).

The folate-containing peptidyl fragment Pte-Glu-(AA)_(n)-Cys-OH (18) isprepared by a polymer-supported sequential approach using theFmoc-strategy on an acid-sensitive Fmoc-Cys(Trt)-Wang resin (16), asshown in Scheme 8.

Referring to Scheme 8, R₁ is Fmoc, R₂ is Trityl, and DIPEA isdiisopropylethylamine. PyBop is applied as the activating reagent toensure efficient coupling. Fmoc protecting groups are removed after eachcoupling step under standard conditions. Appropriately protected aminoacid building blocks, such as Fmoc-Glu-OtBu, N¹⁰-TFA-Pte-OH, and thelike, are used, as described in Scheme 8, and represented by in step (b)by Fmoc-AA-OH. Thus, AA refers to any amino acid starting material, thatis appropriatedly protected.

The coupling sequence (steps (a) & (b)) involving Fmoc-AA-OH isperformed “n” times to prepare solid-supported peptide (17), where n isan integer and may equal 0 to about 100. Following the last couplingstep, the remaining Fmoc group is removed, and the peptide issequentially coupled to a glutamate derivative (step (c)), deprotected,and coupled to TFA-protected pteroic acid (step (d)). Subsequently, thepeptide is cleaved from the polymeric support upon treatment withtrifluoroacetic acid, ethanedithiol, and triisopropylsilane (step (e)).These reaction conditions result in the simultaneous removal of thet-Bu, t-Boc, and Trt protecting groups. The TFA protecting group isremoved upon treatment with base (step (f)) to provide thefolate-containing Cys-containing peptidyl fragment (18).

Drug conjugates are prepared by reacting folate derivative (18)(0.9-0.95 eq.) with drug thiosulfonate (15) in deionized water (0.04 M,pH adjusted to 7 with 0.1 N NaHCO₃) under argon for about 30 minutes,forming a disulfide bond. Upon evaporation of the methanol in vacuo, theconjugate may be purified by preparative HPLC (Prep Novapak HR C1819×300 mM column; mobile phase (A)-1.0 mM phosphate buffer, pH=6;organic phase (B)-acetonitrile; conditions-gradient from 99% A and 1% Bto 50% A and 50% B in 30 minutes, flow rate=15 mL/minute).

Examples 6a-6f

Examples 6a-6f were prepared by the following general procedure. To awell stirred solution of the corresponding drug having an —OH group (1eq. in dry CH₂Cl₂ or dry THF) was added under argon6-(trifluoromethyl)benzotriazolyl 2-(2′-pyridyldithioethyl carbonate(1.3 eq.) and N,N-dimethylaminopyridine (1.5 eq.). The reaction mixturewas stirred for 3 h, and the pyridyldithio-derivatized drug was isolatedby silica chromatography (>65% for each example). The correspondingpeptidyl fragment (0.5 eq.), prepared according to the proceduresdescribed herein and alternatively by conventional procedures, such asthose described in U.S. Patent Application Publication No.US-2005-0002942-A1, was dissolved in DMSO. To the resulting clear yellowsolution was added the pyridyl-dithio derivatized drug. After 30 min,the reaction was completed and the conjugate purified by HPLC. In thecase of Example 6e, the peptidyl fragment Pte-Glu-Asp-Arg-Asp-Asp-Cys-OHwas first dissolved in water, and the pH of the solution was adjusted to2.5 with 0.1 N HCl, causing the peptidyl fragment to precipitate. Thepeptidyl fragment was collected by centrifugation, dried, and dissolvedin DMSO for subsequent reaction with the pyridyldithio-derivatized drug.

Example 6a

¹H NMR (DMSO-d₆) δ 4.7 (d, 1H), 4.95 (t, 1H), 6.7 (d, 4H), 6.9 (t, 1H),7.95 (d, 2H), 8.1 (d, 2H), 8.2 (m, 1H), 8.3 (s, 1H), 8.4 (s, 1H), 8.7(s, 1H), 10.2 (s, 1H), 11.8 (d, 2H).

Example 6b

ES MS (m−H)⁻ 1436.4, (m+H)⁺ 1438.3.

Example 6c

¹H NMR (DMSO-d₆/D₂O) δ 1.0 (s, 1H), 1.1 (s, 1H), 1.6 (s, 1H), 1.8 (s,1H), 2.1 (s, 1H), 2.25 (s, 3H), 2.65 (dd, 2H), 3.7 (d, 1H), 4.4 (t, 1H),4.55 (q, 2H), 4.6 (d, 2H), 4.95 (d, 1H), 5.9 (t, 1H), 6.15 (s, 1H), 6.6(d, 2H), 7.85 (d, 2H), 7.95 (d, 2H), 8.6 (s, 1H), 8.95 (d, 1H).

Example 6d

¹H NMR (DMSO-d₆/D₂O) δ 1.0 (s, 1H), 1.1 (s, 1H), 1.65 (s, 1H), 2.1 (s,1H), 2.25 (s, 3H), 2.6 (dd, 2H), 3.25 (dd, 1H), 3.6 (t, 2H), 3.7 (d,1H), 4.4 (t, 1H), 4.6 (d, 1H), 4.95 (d, 1H), 5.9 (t, 1H), 6.2 (s, 1H),6.6 (d, 2H), 7.7 (t, 1H), 7.9 (d, 2H), 7.95 (d, 2H), 8.6 (s, 1H), 9.1(d, 2H).

Example 6e

¹H NMR (DMSO-d₆/D₂O) δ 10.85 (d, 2H), 1.05 (d, 2H), 1.2 (d, 2H), 1.7 (d,2H), 3.95 (d, 1H), 4.05 (dd, 1H), 5.4 (dd, 1H), 5.7 (dd, 1H), 6.65 (d,2H), 7.6 (d, 2H), 7.95 (s, 1H), 8.65 (s, 1H).

Example 6f

ES MS (m+H)⁺ 1487.23; ¹H NMR (DMSO-d₆/D₂O) δ 0.9 (t, 2H), 1.3 (t, 2H),2.15 (t, 2H), 3.2 (dd, 1H), 4.0 (t, 1H), 4.15 (q, 1H), 5.3 (s, 2H), 5.5(s, 2H), 6.6 (d, 2H), 7.0 (s, 1H), 7.4 (m, 2H), 7.55 (d, 2H), 8.0 (d,2H), 8.6 (s, 1H).

Example 7

The intermediate 4-(2-pyridinyldithio)benzylcarbonate of SN 38(10-hydroxy-7-ethylcamptothecin) was prepared according to the proceduredescribed by P. Senter et al., J. Org. Chem. 1990, 55, 2875, thedisclosure of which is incorporated herein by reference. The peptidylfragment Pte-Glu-Asp-Arg-Asp-Cys-OH, prepared as described herein, wasdissolved in DMSO, and to the resulting clear yellow solution was addedthe pyridyl-dithio derivatized drug. After 30 min, the reaction wascompleted and the conjugate purified by HPLC; ES MS (m+H)⁺ 1425.38; ¹HNMR (DMSO-d₆/D₂O) δ 0.9 (t), 1.15 (t), 3.9 (t), 4.0 (t), 4.25 (t), 5.1(m), 5.2 (s), 5.4 (s), 6.55 (d), 7.25 (d), 7.35 (d), 7.5 (d), 7.9 (d),8.55 (s).

Example 8

The compound of Example 8 was prepared from the peptidyl fragmentPte-Glu-Asp-Arg-Asp-Asp-Cys-OH, prepared according to the proceduresdescribed herein and alternatively by conventional procedures, such asthose described in U.S. Patent Application Publication No.US-2005-0002942-A1. The peptidyl fragment also reacted with either thethiosulfonate or pyridyldithio-activated vinblastine to form Example 8.The pyridyldithio-activated vinblastine intermediates were preparedusing the procedures described herein for other examples.

Examples 9-13

The compounds of Examples 9-13 were prepared according to the proceduresgenerally described herein, and were characterized by electrospray massspectroscopy (ES MS), and other spectroscopic techniques, including 1Dand 2D NMR, and UV, illustrative results of which are described herein.

Example 9

UV (nm) 233 (max), 255, 280; ¹H NMR (D₂O, NaOD, CD₃CN) δ 1.15 (d, 3H),2.3 (s, 3H), 3.6 (s, 1H), 3.85 (s, 3H), 4.9 (s, 1H), 5.3 (s, 1H), 6.5(d, 2H), 7.3 (m, 1H), 7.5 (d, 2H), 7.65 (d, 2H), 8.4 (s, 1H).

Example 10

ES MS (m+H)⁺ 1382.3, (m+Na)⁺ 1405.4.

Example 11

Example 12

Example 13

The foregoing exemplary embodiments are intended to be illustrative ofthe invention, and should not be interpreted or construed as limiting inany way the invention as described herein. For example, compoundsgenerally represented by the following illustrative vitamin-drugconjugate are to be included in the invention as described herein

where R¹ and R² are each independently hydrogen or alkyl, such asmethyl; and l_(H) is a heteroatom, such as oxygen, sulfur, optionallysubstituted nitrogen, or optionally protected nitrogen, and the like.

1.-6. (canceled)
 7. A compound of the formula

wherein X¹ are each independently selected leaving groups, where each of said leaving groups is displaceable by an independently selected nucleophile; Q is selected from the group consisting of

where R^(a) and R^(b) are each independently selected from the group consisting of hydrogen and alkyl; or R^(a) and R^(b) are taken together with the attached carbon atom to form a carbocyclic ring; n and m are integers from 1 to about 4; and * represents the point of attachment; and X² is optionally substituted heteroaryloxy.
 8. The compound of claim 7 wherein Q is


9. The compound of claim 8 wherein n is
 1. 10. The compound of claim 8 wherein R^(a) and R^(b) are selected from the group consisting of hydrogen and lower alkyl.
 11. The compound of claim 8 wherein R^(a) and R^(b) are each hydrogen.
 12. The compound of claim 8 wherein R^(a) and R^(b) are taken together with the attached carbon atom to form a carbocyclic ring.
 13. The compound of claim 8 wherein R^(a) and R^(b) are taken together with the attached carbon atom to form cyclopropyl.
 14. The compound of claim 7 wherein Q is


15. The compound of claim 14 wherein m is
 1. 16. The compound of claim 7 wherein Q is


17. The compound of claim 16 wherein m is
 1. 18. The compound of claim 7 wherein the nucleophile is a drug, a vitamin, an imaging agent, a diagnostic agent, or another bivalent linker.
 19. The compound of claim 7 wherein the X¹ is optionally substituted heteroarylthio.
 20. The compound of claim 7 wherein the X² is optionally substituted benzotriazolyloxy.
 21. A process for preparing a conjugate of the formula V-L-D, V-L-IA, or V-L-DA; wherein V is the conjugate base of a vitamin receptor-binding moiety or analog or derivative thereof; D is the conjugate base of a drug or analog or derivative thereof; IA is the conjugate base of an imaging agent or analog or derivative thereof; DA is the conjugate base of a diagnostic agent or analog or derivative thereof; and L is a linker comprising a compound of the formula

wherein Q is selected from the group consisting of

where R^(a) and R^(b) are each independently selected from the group consisting of hydrogen and alkyl; or R^(a) and R^(b) are taken together with the attached carbon atom to form a carbocyclic ring; n and m are integers from 1 to about 4; and * represents the point of attachment; the process comprising the step of reacting a compound of the formula V-H with a compound of claim
 1. 22. The process of claim 21 further comprising the step of adding a base.
 23. The process of claim 21 wherein V-H includes a thiol group, and the thiol group displaces X¹ to form a disulfide bond.
 24. A process for preparing a conjugate of the formula V-L-D, V-L-IA, or V-L-DA; wherein V is the conjugate base of a vitamin receptor-binding moiety or analog or derivative thereof; D is the conjugate base of a drug or analog or derivative thereof; IA is the conjugate base of an imaging agent or analog or derivative thereof; DA is the conjugate base of a diagnostic agent or analog or derivative thereof; and L is a linker comprising a compound of the formula

wherein Q is selected from the group consisting of

where R^(a) and R^(b) are each independently selected from the group consisting of hydrogen and alkyl; or R^(a) and R^(b) are taken together with the attached carbon atom to form a carbocyclic ring; n and m are integers from 1 to about 4; and * represents the point of attachment; the process comprising the step of reacting a compound of the formula D-H, IA-H, or DA-H with a compound of claim
 1. 25. The process of claim 24 further comprising the step of adding a base.
 26. The process of claim 24 wherein D-H, IA-H, or DA-H includes a thiol group, and the thiol group displaces X¹ to form a disulfide bond.
 27. A process for preparing a conjugate of the formula V-L-D, V-L-IA, or V-L-DA; wherein V is the conjugate base of a vitamin receptor-binding moiety or analog or derivative thereof; D is the conjugate base of a drug or analog or derivative thereof; IA is the conjugate base of an imaging agent or analog or derivative thereof; DA is the conjugate base of a diagnostic agent or analog or derivative thereof; and L is a linker comprising a compound of the formula

wherein Q is selected from the group consisting of

where R^(a) and R^(b) are each independently selected from the group consisting of hydrogen and alkyl; or R^(a) and R^(b) are taken together with the attached carbon atom to form a carbocyclic ring; n and m are integers from 1 to about 4; and * represents the point of attachment; the process comprising the step of reacting a compound of the formula V-L¹-H with a compound of claim 1, where L¹ comprises a fragment of L.
 28. The process of claim 27 further comprising the step of adding a base.
 29. The process of claim 27 wherein V-L¹-H includes a thiol group, and the thiol group displaces X¹ to form a disulfide bond. 